chronic skin diseases
Almirall’s paediatric registration of Ebglyss for atopic dermatitis gets EMA acceptance
Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood
Evotec appoints Ingrid Müller as Chief Operating Officer
Most recently, Müller held senior international leadership roles at CureVac, Sanofi and Fresenius Kabi
Almirall celebrates new offices in China to advance innovation in dermatology
The company’s R&D and commercial expertise represent valuable capabilities for future Chinese partners
Moderna and Merck announce data from melanoma combination therapy study
Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths
Sandoz to acquire Just-Evotec Biologics to strengthen biosimilar development and manufacturing capabilities
Acquisition will add in-house continuous manufacturing expertise and expand Sandoz’s biosimilar production capacity
Almirall and Absci expand AI dermatological drug discovery partnership
The alliance has already led to the delivery of functional antibody leads against a difficult-to-drug target
NHS programme to give melanoma patients fast-track access to skin cancer vaccine
The phase 2 study will evaluate Scancell's iSCIB1+ in patients with advanced unresectable melanoma
Almirall hosts Skin Academy to advance skin science and dermatology treatments
The conference will cover actinic keratosis, psoriasis, atopic dermatitis and other skin diseases
Regeneron shares positive phase 3 results for Libtayo in high-risk skin cancer
Approximately 1.8 million cases of cutaneous squamous cell carcinoma are diagnosed in the US every year
Eli Lilly/Almirall share positive long-term results for Ebglyss in atopic dermatitis
The inflammatory skin condition occurs in approximately 7.3% of adults in the US
Merck shares positive ten-year results for Keytruda in advanced melanoma
More than 100,640 cases of the skin cancer are expected to be diagnosed in the US this year
Almirall announces NICE recommendation for Ebglyss in atopic dermatitis
The inflammatory skin condition affects about 5.2 million adults and 2.5 million children in the UK